Compare Ascendis Pharma A/S (ASND) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Total World Stock Index Fund ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Vanguard Total World Stock Index Fund ETF trades at $157. Which is the better fit depends on your goals.
| ASND | VT | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $159.35 |
52-Week Low | $163.32 | $128.41 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Vanguard Total World Stock ETF (VT) trades at $157.63, up 0.4% with a bullish technical outlook from moving averages. The ETF maintains global diversification with over 10,000 holdings across developed and emerging markets. Recent news highlights competitive positioning against peers like SPDW and SCHF, with a modest 1.6% dividend yield and low 0.06% expense ratio. Technical indicators show support at $155 and resistance at $159, with RSI levels in neutral territory.
VT offers broad global equity exposure with cost efficiency, though emerging market volatility and currency risks persist. The ETF's neutral oscillator signals and mixed ADX readings suggest near-term consolidation potential. Long-term growth hinges on global economic stability and diversification benefits outweighing sector-specific downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
